The effect of 2-ethyl-6-methyl-3-hydroxypyridine succinate on the cortisol level in the blood of patients with acute myocardial infarction and cognitive disorders

Authors

DOI:

https://doi.org/10.24959/cphj.18.1452

Keywords:

2-ethyl-6-methyl-3-hydroxypyridine succinate, quercetine, acute myocardial infarction, cortisol

Abstract

Annually about 50 thousand cases of acute myocardial infarction (AMI) are recorded in Ukraine. One of the causes leading to unfavorable course of AMI is cognitive disorders, which are beyond the age limit in half of the cases.
Aim. To study the effect of 2-ethyl-6-methyl-3-hydroxypyridine succinate on the cortisol level in the blood of patients with AMI and cognitive disorders.
Materials and methods. The study included 70 patients with AMI and cognitive dysfunction under 60 years old. Additionally, the cortisol levels in the blood serum were studied. Depending on the type of treatment the patients were divided into 2 groups: Group 1 (n=35) – patients with the standard treatment scheme in case of AMI and quercetine, Group 2 (n=35) – patients together with the standard treatment and quercetine received 2-ethyl-6-methyl-3-hydroxypyridine succinate.
Results. The study showed that in Group 1 cortisol was increased in 86 % of patients, while in Group 2 it was increased in 80 %. On the background of the treatment provided in Group 1 the cortisol levels were elevated in 45.70 % of patients, while in Group 2 the increase was in 22.85 % of patients. It was found that 2-ethyl-6-methyl-3-hydroxypyridine succinate added to the standard treatment scheme gave a significant decrease of the cortisol levels in the blood of patients in Group 2, whereas in patients receiving the standard therapy and quercetine the regression of the blood serum cortisol was significantly lower.
Conclusions. The study has made it possible to prove that 2-ethyl-6-methyl-3-hydroxypyridine succinate used along with the standard treatment leads to significant decrease of the cortisol levels in the blood serum and cognitive disorders in patients with AMI under 60 years old.

References

World Health Organization: WHO. Available at : http://www.who.int/en/

Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R. (2017). Heart Disease and Stroke Statistics – 2017 Update: A Report From the American Heart Association. Circulation, 135 (10), e146–e603. doi: 10.1161/cir.0000000000000491

Kozhukhov, S. N. (2017). Sertseva nedostatnist ta komorbidni stany, 1, 39–45.

Hadziuk V. A. (2014). Ukrainskyi kardiolohichnyi zhurnal, 3, 45–52.

Nichols, M., Townsend, N., Scarborough, P., Rayner, M. (2012). Evropean cardiovascular disease statistics 2012 edition, 1–125.

Dowdy, D. W., Eid, M. P., Sedrakyan, A., Mendez–Tellez, P. A., Pronovost, P. J., Herridge, M. S., Needham, D. M. (2005). Quality of life in adult survivors of critical illness: A systematic review of the literature. Intensive Care Medicine, 31 (5), 611–620. doi: 10.1007/s00134–005–2592–6

Jutla, S. K., Yuyun, M. F., Quinn, P. A., Ng, L. L. (2014). Plasma cortisol and prognosis of patients with acute myocardial infarction. Journal of Cardiovascular Medicine, 15 (1), 33–41. doi: 10.2459/jcm.0b013e328364100b

De Rooij, S. R. (2013). Blunted cardiovascular and cortisol reactivity to acute psychological stress: A summary of results from the Dutch Famine Birth Cohort Study. International Journal of Psychophysiology, 90 (1), 21–27. doi: 10.1016/j.ijpsycho.2012.09.011

Published

2018-03-14

Issue

Section

Clinical Pharmacology and Pharmacotherapy